Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bolt Biotherapeutics (BOLT) Income from Continuing Operations (2020 - 2025)

Bolt Biotherapeutics' Income from Continuing Operations history spans 6 years, with the latest figure at 7226000.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations rose 52.39% year-over-year to 7226000.0; the TTM value through Sep 2025 reached 42835000.0, up 38.6%, while the annual FY2024 figure was 67793000.0, 2.03% up from the prior year.
  • Income from Continuing Operations for Q3 2025 was 7226000.0 at Bolt Biotherapeutics, up from 8611000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 7226000.0 in Q3 2025 and bottomed at 27157000.0 in Q4 2021.
  • The 5-year median for Income from Continuing Operations is 18057000.0 (2023), against an average of 18131263.16.
  • The largest annual shift saw Income from Continuing Operations plummeted 113.27% in 2021 before it surged 59.37% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 27157000.0 in 2021, then grew by 26.37% to 19997000.0 in 2022, then rose by 10.47% to 17903000.0 in 2023, then rose by 10.99% to 15936000.0 in 2024, then surged by 54.66% to 7226000.0 in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Income from Continuing Operations are 7226000.0 (Q3 2025), 8611000.0 (Q2 2025), and 11062000.0 (Q1 2025).